Author

Erika Isaksson-Friman

Observed names: E Friman, E. Friman, E. Isaksson Friman, E. Isaksson-Friman, E. Isakssonfriman, Erika Isaksson Friman, Erika Isaksson Friman, Isaksson Friman, Erika

Institution: Saint Göran Hospital

Observed institutions: Karolinska University Hospital, Saint Göran Hospital

ORCID: 0000-0001-8055-4297

Observed ORCID: 0000-0001-8055-4297

OpenAlex ID: A5040974297

Risk Factors for Hormone Receptor-Defined Breast Cancer in Postmenopausal Women

2006 · Lena U. Rosenberg, Kristjana Einarsdóttir, et al. · Cancer Epidemiology Biomarkers & Prevention · 124

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial

2021 · Thomas Hatschek, Theodoros Foukakis, et al. · JAMA Oncology · 62

PDF

Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

2022 · Alexios Matikas, Hemming Johansson, et al. · Clinical Cancer Research · 46

Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?

2019 · Jonas C. S. Bergh, Anne Andersson, et al. · Journal of Clinical Oncology · 22

ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden—a phase III randomised double-blinded placebo-controlled study

2023 · Kenny A Rodriguez-Wallberg, Hanna Pauline Nilsson, et al. · BMJ Open · 9

PDF

The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial

2024 · Yajing Zhu, Ioannis Zerdes, et al. · Breast Cancer Research and Treatment · 7

PDF

97O PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels

2020 · T. Hatschek, A. Andersson, et al. · Annals of Oncology · 5

Severe Photo Toxicity Recalled by Docetaxel

2018 · Emma K. Johansson, Britta Krynitz, et al. · Case Reports in Oncology · 5

Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial

2026 · Alexios Matikas, Evangelos Tzoras, et al. · Nature Communications · 2

PDF

2019 · Yvonne Brandberg, Anne Andersson, et al. · Journal of Clinical Oncology · 2

122P Primary results and biomarker analysis from PREDIX LumB: A prospective randomized phase II trial investigating sequence of neoadjuvant chemotherapy and palbociclib/endocrine therapy for luminal breast cancer

2024 · A. Matikas, J. Bjöhle, et al. · ESMO Open · 1

PDF

Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.

2022 · Yajing Zhu, Kang Wang, et al. · Journal of Clinical Oncology · 1

Hormone therapy and estrogen receptor expression in breast cancer

2006 · E. Isaksson Friman, M. Mahlman, et al. · Acta Oncologica · 1

PDF

Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial

2026 · Pascual, Tomás, Gavilá, Joaquín, et al. · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)

Supplementary Figure S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial